The invention relates to a pharmaceutically acceptable acid addition salt of: (i) S-oxprenolol; and (ii) phosphoric acid. Medical uses of the salt and compositions comprising the salt are also described.
The invention relates to a pharmaceutically acceptable acid addition salt of: (i) S-pindolol; and (ii) an organic acid, wherein the organic acid has: a pKa1 of greater than or equal to 2.5; and a chemical formula of CxHy(CO2H)z, where x is from 1 to 10, y is from 2 to 20 and z is 1 or 2. The pharmaceutically acceptable acid addition salt is useful in treating conditions such as cachexia, sarcopenia, a neuromuscular disorder and muscle weakness.
The invention relates to a solid pharmaceutical formulation suitable for oral administration comprising: (a) an active agent which is S-pindolol or a pharmaceutically acceptable salt thereof; (b) a starch excipient in an amount of at least 15.0% by weight relative to the total weight of the formulation; and (c) a cellulose excipient in an amount of at least 30.0% by weight relative to the total weight of the formulation. Also provided is the solid pharmaceutical formulation for use in therapy, for instance in the treatment of cachexia.
The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
The invention relates to a pharmaceutically acceptable acid addition salt of: (i) S- oxprenolol; and (ii) phosphoric acid. Medical uses of the salt and compositions comprising the salt are also described.
C07C 217/34 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
z, where x is from 1 to 10, y is from 2 to 20 and z is 1 or 2. The pharmaceutically acceptable acid addition salt is useful in treating conditions such as cachexia, sarcopenia, a neuromuscular disorder and muscle weakness.
The invention relates to a solid pharmaceutical formulation suitable for oral administration comprising: (a) an active agent which is S-pindolol or a pharmaceutically acceptable salt thereof; (b) a starch excipient in an amount of at least 15.0 % by weight relative to the total weight of the formulation; and (c) a cellulose excipient in an amount of at least 30.0 % by weight relative to the total weight of the formulation. Also provided is the solid pharmaceutical formulation for use in therapy, for instance in the treatment of cachexia.
The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
The invention relates to a pharmaceutically acceptable acid addition salt of: (i) S- pindolol; and (ii) an organic acid, wherein the organic acid has: a pKa1 of greater than or equal to 2.5; and a chemical formula of CxHy(CO2H)z, where x is from 1 to 10, y is from 2 to 20 and z is 1 or 2. The pharmaceutically acceptable acid addition salt is useful in treating conditions such as cachexia, sarcopenia, a neuromuscular disorder and muscle weakness.
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical, medical and therapeutic substances and preparations; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of cancers, and of severe or chronic illnesses and diseases; pharmaceutical, medical and therapeutic substances and preparations for treatment and management of physical function; pharmaceutical, medical and therapeutic substances and preparations for treatment and prevention of muscle wasting; pharmaceutical, medical and therapeutic substances and preparations for treatment and management of patient tolerance of therapies, in particular anticancer therapy; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of cachexia, in particular cancer cachexia; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of the side effects of medical treatments, in particular of cancer treatments; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the lung; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the kidney; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the heart; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the liver; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the brain; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic heart failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic renal failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic liver failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic obstructive pulmonary disease; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of neurological-muscular disorders Information, advisory and consultancy services relating to medicine and healthcare; medical and surgical diagnosis and treatment services; medical analysis and reporting services relating to the treatment of patients; assessment and monitoring of patients; preparation of data and reports relating to medicine and healthcare; medical testing services relating to the diagnosis and treatment of illnesses, diseases and medical conditions; providing information relating to the management, preparation and dispensing of medications; medical, health, dentistry, veterinary and pharmaceutical services; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to severe or chronic illnesses and diseases; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of cancers, and of severe or chronic illnesses and diseases; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to physical function and muscle wasting; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to patient tolerance of therapies, in particular anticancer therapy; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of cachexia, in particular cancer cachexia; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of the side effects of medical treatments, in particular of cancer treatments; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the lung; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the kidney; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the heart; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the liver; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the brain; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic heart failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic renal failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic liver failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic obstructive pulmonary disease; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of neurological-muscular disorders; advisory, information and consultancy services relating to all the aforesaid services
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical, medical and therapeutic substances and preparations; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of cancers, and of severe or chronic illnesses and diseases; pharmaceutical, medical and therapeutic substances and preparations for treatment and management of physical function; pharmaceutical, medical and therapeutic substances and preparations for treatment and prevention of muscle wasting; pharmaceutical, medical and therapeutic substances and preparations for treatment and management of patient tolerance of therapies, in particular anticancer therapy; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of cachexia, in particular cancer cachexia; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of the side effects of medical treatments, in particular of cancer treatments; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the lung; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the kidney; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the heart; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the liver; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the brain; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic heart failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic renal failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic liver failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic obstructive pulmonary disease; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of neurological-muscular disorders; all goods previously mentioned not for use in the field of physiologic, kinesiologic, osteopathic and orthopedic treatments as well as treatment of wounds. Information, advisory and consultancy services relating to medicine and healthcare; medical and surgical diagnosis and treatment services; medical analysis and reporting services relating to the treatment of patients; assessment and monitoring of patients; preparation of data and reports relating to medicine and healthcare; medical testing services relating to the diagnosis and treatment of illnesses, diseases and medical conditions; providing information relating to the management, preparation and dispensing of medications; medical, health, dentistry, veterinary and pharmaceutical services; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to severe or chronic illnesses and diseases; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of cancers, and of severe or chronic illnesses and diseases; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to physical function and muscle wasting; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to patient tolerance of therapies, in particular anticancer therapy; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of cachexia, in particular cancer cachexia; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of the side effects of medical treatments, in particular of cancer treatments; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the lung; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the kidney; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the heart; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the liver; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the brain; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic heart failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic renal failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic liver failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic obstructive pulmonary disease; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of neurological-muscular disorders; advisory, information and consultancy services relating to all the aforesaid services; all services previously mentioned not for use in the field of physiologic, kinesiologic, osteopathic and orthopedic treatments as well as treatment of wounds.
17.
S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING MUSCLE WEAKNESS
The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.
The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertalol, or bopindolol are preferred for this purpose.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
The present invention provides a means for prevention and treatment of cachexia and other chronic illnesses including but not limited to the promotion of weight gain, reduction or prevention of weight loss by administration of a substance that both reduces the sensitivity of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propranolol, tertatolol or bopindolol are preferred for this purpose.
The present invention relates to use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a
The invention relates to a solid pharmaceutical formulation suitable for oral administration comprising: (a) an active agent which is S-pindolol or a pharmaceutically acceptable salt thereof; (b) a starch excipient in an amount of at least 15.0 % by weight relative to the total weight of the formulation; and (c) a cellulose excipient in an amount of at least 30.0 % by weight relative to the total weight of the formulation. Also provided is the solid pharmaceutical formulation for use in therapy, for instance in the treatment of cachexia.
The invention relates to a pharmaceutically acceptable acid addition salt of: (i) S- pindolol; and (ii) an organic acid, wherein the organic acid has: a pKa1 of greater than or equal to 2.5; and a chemical formula of CxHy(CO2H)z, where x is from 1 to 10, y is from 2 to 20 and z is 1 or 2. The pharmaceutically acceptable acid addition salt is useful in treating conditions such as cachexia, sarcopenia, a neuromuscular disorder and muscle weakness.
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
The present invention provides a means for prevention and treatment of cachexia and other chronic illnesses including but not limited to the promotion of weight gain, reduction or prevention of weight loss by administration of a substance that both reduces the sensitivity of beta-adrenergic receptors and of 5-HTla receptors. (S)- pindolol, (S)-propranolol, tertatolol or bopindolol are preferred for this purpose.
A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
